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OJECTIVES: The aim was to evaluate the ability of bilateral superficial cervical plexus blockade to control pain
and to reduce the side effects of general anesthesia in patients submitted to thyroidectomy.
METHODS: In this randomized controlled trial, we prospectively studied 100 consecutive patients who under-
went total thyroidectomy. The simple random patient sample was divided into two groups: 50 patients received
general anesthesia alone (group 1 [G1]), and 50 patients received general anesthesia with bilateral superficial
cervical plexus blockade (group 2 [G2]). Statistical analyses were performed, and a 5% significance level was
adopted.
RESULTS: The mean arterial blood pressure and heart rate were 12% lower in G2 patients than in G1 patients
60 minutes after surgery (101 mmHg for G1 vs. 92.3 mmHg for G2; po0.001). G2 patients reported less pain than
G1 patients, and opioid consumption was lower in G2 patients than in G1 patients, not upon postanesthesia
care unit arrival, but at 30 minutes (2% vs. 34%; po0.001, respectively), 45 minutes (0% vs. 16%; p=0.006,
respectively), and 4 hours postoperatively (6% vs. 20%; p=0.037, respectively). The incidence of nausea and
vomiting was lower in G2 patients than in G1 patients from 45 minutes (0% vs. 16%; p=0.006, respectively) to
8 hours postoperatively (0% vs. 14%; p=0.012, respectively).
CONCLUSIONS: The present study demonstrated that the combination of bilateral superficial cervical plexus
blockade with general anesthesia for thyroidectomy is feasible, safe, and effective for achieving pain control
and improving patient outcomes.
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’ INTRODUCTION
Pain control is a necessary aspect of care during the post-
operative period. Pain is considered the fifth vital sign,
and its control reduces clinical and surgical complications,
reduces the incidence of side effects, and improves patient
outcomes (1).
Management of the postoperative period after thyroidect-
omy, which extends from extubation to hospital discharge,
is crucial for the success of the procedure. Arterial blood
pressure control and the incidence of postoperative nausea
and vomiting (PONV) are related to reduced postoperative
bleeding and cervical hematoma. However, uncontrolled
pain can increase postoperative bleeding and cervical hema-
toma via the adrenergic pathway and catecholamine secre-
tion. Furthermore, the concomitant use of analgesics, such as
opioids, which have side effects that include nausea and
vomiting, may worsen a patient’s clinical condition (2-4).
The superficial cervical plexus innervates the anterior
cervical skin through the primary rami of C2-C4. For thyro-
idectomy, the effectiveness of bilateral superficial cervical
plexus blockade (BSCPB) in combination with general anes-
thesia remains controversial with respect to pain control
and a reduction in the side effects of postoperative general
anesthesia (5). The aim of this randomized controlled trial
was to evaluate the influence of BSCPB on pain control and
on the ability to reduce the side effects of general anesthesia
in patients submitted to thyroidectomy.DOI: 10.6061/clinics/2019/e605
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’ METHODS
This randomized controlled trial was approved by the
Institutional Research Ethics Board. After obtaining informed
consent, we prospectively studied a series of 100 consecutive
patients who underwent total thyroidectomy at a tertiary hos-
pital over a period of 2 years.
The inclusion criteria were as follows: patients with
American Society of Anesthesiologists (ASA) physical status
I or II, aged between 25 and 65 years old, and with a body
mass index (BMI) between 20 and 30. The exclusion criteria
were as follows: patients with ASA physical status III or IV,
patients with rheumatic or neurological diseases (periphe-
ral or central neuropathies), and patients being treated
for chronic pain because of the long-term use of corticoster-
oids, opioids, or other pain medications that may affect the
results.
The simple random patient sample was divided into two
groups: 50 patients received total intravenous general anes-
thesia (TIVA) (group 1 [G1]), and 50 patients received TIVA
in combination with BSCPB (group 2 [G2]). Patients were
informed in advance that they would be assigned to either
the TIVA group or the TIVA plus BSCPB group.
All anesthetic procedures were performed by the same
anesthesiologist in both groups; all surgical procedures were
performed by the same head and neck surgeon V.J.F.A.F.
Evaluation Before Anesthesia
Both groups were evaluated by the same anesthesiologist
before anesthesia. Anesthesia was induced by administering
0.75 mg/kg intramuscular midazolam 30 minutes before the
surgery and prior to entering the operating room.
Anesthesia in the Operating Room (OR)
The following procedures were adopted at the OR:
1) Monitoring of the G1 and G2 patients was performed
using continuous cardioscopy, pulse oximetry, noninva-
sive arterial blood pressure (NIABP), heart rate (HR),
continuous capnography, temperature determined by an
esophageal thermometer, and bispectral index (BIS). The
data were recorded at three time points: M1, before
anesthesia induction; M2, just after induction and oral
intubation; and M3, just after extubation.
2) The blood glucose levels of the G1 and G2 patients were
maintained between 100 and 150 mg/dl and evaluated at
M1 and M3.
3) Anesthesia induction in G1 patients was performed as
follows: after 20-gauge peripheral venous catheterization
and preoxygenation for 5 minutes via a face mask at an
oxygen inspired fraction (FiO2) of 100%, anesthesia was
slowly induced by an intravenous bolus of fentanyl at
2 mcg/kg, propofol at 2.5 mg/kg, and a bolus of cisa-
tracurium at 0.1 mg/kg. After 10 minutes of facial mask
ventilation and a BIS under 40, tracheal intubation was
performed. The mechanical ventilation parameters were a
tidal volume of 8 ml/kg, positive end-expiratory pressure
(PEEP) of 5 mmHg, respiratory frequency to maintain
capnography between 30 and 35 mmHg, and FiO2 of 50%
(oxygen and air). The anesthesia was maintained by the
continuous infusion of propofol at an average dose of 0.05
mg/kg/minute and remifentanil at 0.5 mcg/kg/minute
(to maintain a BIS under 60 and the mean arterial blood
pressure at 10% to 20% below the basal awake levels).
Neither additional doses of fentanyl nor cisatracurium
were administered. For intraoperative hydration, Ringer’s
lactate solution was infused at 5 ml/kg/hour.
4) Anesthesia induction in G2 patients was performed as
follows: after anesthesia induction as described above
for G1 patients and before the beginning of surgery, the
patients’ heads were rotated to the contralateral side of
the blockade. After antisepsis, the posterior border of the
clavicular sternocleidomastoid head muscle (inserts from
the mastoid process to the clavicle) was identified. The
puncture was made at the midpoint of a line drawn from
the mastoid to the C6 transverse process (Chassaignac’s
tubercle), which may coincide with the junction between
the external jugular vein and the muscle; here, a 22-gauge
needle was inserted. After aspiration and no evidence
of blood, 5 ml of 0.75% ropivacaine was perpendicularly
injected into the subcutaneous space at this point. The
needle was redirected along this plane superiorly and
inferiorly. After test aspiration, 5 ml of 0.75% ropivacaine
was injected into the subcutaneous space. This technique
was performed bilaterally.
5) After induction in both the G1 and G2 patients, 40 mg
intravenous pantoprazole, 2 g cefazolin, 30 mg ketorolac,
8 mg ondansetron, and 10 mg dexamethasone were admi-
nistered. At the end of the surgery, the patients were
extubated in a delicate manner that avoided coughing
and were then transferred to the postanesthesia care unit
(PACU).
Thyroidectomy
All enrolled patients were submitted to total thyroidect-
omy by an anterior cervicotomy, utilizing the conventional
technique and without the use of any hemostatic instrument.
None of the patients underwent cervical drainage.
Procedures in the PACU
The prescription for the G1 and G2 patients was as
follows: 5 L/minute oxygen nebulization, 30 degrees of head
elevation, and 0.15 mg/kg nalbuphine, as needed for pain.
Pain was evaluated by a visual analog scale (VAS) that
ranged from 0 to 10, with a score of 0 indicating no pain;
a score of 1 to 3 indicating mild pain; a score of 4 to 7 indi-
cating moderate pain; and a score of 8 to 10 indicating
intense pain. If the VAS score was above 3, then medica-
tion was administered. These doses were repeated every
20 minutes as necessary. Each patient remained in the PACU
for 60 minutes. During this period, the following data were
recorded every 15 minutes:
1) Vital signs: noninvasive blood pressure (NIBP), HR, pulse
oximetry, axillary temperature, and glycemia (if the
patient has been previously diagnosed with diabetes);
2) Pain by the VAS;
3) The presence or absence of side effects, including shiver-
ing, agitation, dyspnea, nausea and vomiting, cervical
hematoma, and bleeding. Postoperative nausea and vomi-
ting (PONV) were evaluated using the PONV scale (5),
with a score of 1 indicating no nausea; 2 indicating mild
nausea; 3 indicating severe nausea; and 4 indicating vomi-
ting. For scores of 3 and 4, an antiemetic drug was
administered.
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Procedures in the Inpatient Unit (IU)
The prescription for the G1 and G2 patients was as
follows: soft meal, 40 mg intravenous (i.v.) pantoprazole once
per day, 30 mg i.v. ketorolac (8/8 hours), and 0.2 mg/kg i.v.
nalbuphine (6/6 hours) for pain (VAS43); the patients were
additionally administered 8 mg ondansetron if the PONV
score was 3 or 4.
Vital signs, including NIPB, HR, and pulse oximetry, and
the occurrence of side effects (nausea and vomiting, shiver-
ing, agitation, dyspnea, and cervical hematoma) were evalu-
ated every 4 hours.
Statistical Analyses
Categorical variables are presented in tables as absolute (n)
and relative (%) frequencies. The association between groups
was evaluated by the chi-square test, Fisher’s exact test, or
the likelihood ratio test. The quantitative variables were pre-
sented as the mean and standard deviation and were defined
as parametric by the Kolmogorov-Smirnov test. Repeated
measures ANOVA (rm-ANOVA), with Bonferroni’s post hoc
test when necessary, was applied for comparisons between
groups of continuous variables; Student’s t-test was also
used to compare two independent groups of quantitative
data. p-valueso0.05 were considered statistically significant.
’ RESULTS
Among the 100 participants in this study, 18% were men
and 82% were women. The average patient age in G1 was
45 years old, and the average patient age in G2 was 50 years
old. No significant difference was found in ASA physical
status between the groups. The most prevalent comorbidities
in both groups were diabetes (6% in G1 and 14% in G2),
systemic arterial hypertension (28% in G1 and 26% in G2),
and dyslipidemia (12% in G2); however, with the exception
of dyslipidemia, there were no significant differences between
these rates. The main surgical diagnoses were goiter (62% in
both G1 and G2), differentiated carcinoma (38% in G1 and
36% in G2), and toxic goiter (2% in G2); there were no signi-
ficant differences between the groups. In G1, there were two
cases of difficult airways, and intubations with bronchoscopy
were performed by the anesthesiologist. Descriptive data and
the results of homogeneity analysis are described in Table 1.
Data from the OR
The average surgical time was 120 minutes (range: 104-140
minutes), and the average anesthesia time was 135 minutes
(range: 120-150 minutes). There was no significant difference
between the groups (p=0.682, Student’s t-test). The NIABP,
HR and temperature values at the three time points were
similar and had the same behavior over time for the G1 and
G2 patients during the surgery. The comparison between
groups for the OR variables and descriptive data are des-
cribed in Table 2.
Data from the PACU
Upon arrival in the PACU, there was no significant
difference between the NIABP in the two groups. However,
over time (at 15, 30, 45, and 60 minutes), significant differen-
ces were observed between the two groups. The main NIABP
was significantly lower in G2 patients than in G1 patients
(po0.001; rm-ANOVA). The HR was significantly lower in
G2 patients than in G1 patients at PACU arrival and 15, 30,
45, and 60 minutes after surgery (po0.001; rm-ANOVA and
Bonferroni’s post hoc test). In the PACU, the temperature
data obtained for the two groups were the same, without
significant differences.
There were significant differences (po0.001; Fisher’s exact
test) in the VAS scores at 15 and 30 minutes after arrival in
the PACU. After 15 minutes, 56% of G1 patients reported
pain (VAS43), compared to only 6% of G2 patients. A dose
of nalbuphine was administered. After 30 minutes, 34% of
G1 patients and only 2% of G2 patients reported pain, and
another dose of nalbuphine was necessary. After 45 minutes,
16% of G1 patients reported pain, while none of the patients
in G2 reported pain (p=0.006; Fisher’s exact test). After
60 minutes, there were no significant differences between the
groups.
Opioid consumption was significantly lower in G2 patients
than in G1 patients at 15 and 30 minutes upon arrival in the
PACU (po0.001 for both analyses; Fisher’s exact test). After
15 minutes, 56% of G1 patients required the administration
of nalbuphine compared to only 6% of G2 patients. After
30 minutes, 34% of G1 patients required an additional dose
compared to only 2% of G2 patients. At 45 minutes, 16% of G1
patients required another dose of medication compared to 0%
Table 1 - Descriptive data and homogeneity analysis.
Variable Group 1 Group 2 p-value (test)
Male sex, n (%) 9 (18%) 9 (18%) 1.000 (Pearson’s chi-square)
Age, mean ± SD, years 50±15 46±13 0.119 (Student’s t-test)
BMI, mean ± SD, kg/m2 26±4 27±5 0.361 (Student’s t-test)
ASA, n (%)
I 27 (54%) 21 (42%) 0.230 (Pearson’s chi-square)
II 23 (46%) 29 (58%)
Comorbidities, n (%)
Systemic arterial hypertension 14 (28%) 13 (26%) 0.822 (Pearson’s chi-square)
Dyslipidemia 0 (0%) 6 (12%) 0.012 (Fisher’s exact test)
Diabetes 3 (6%) 7 (14%) 0.182 (Fisher’s exact test)
Obesity 3 (6%) 5 (10%) 0.715 (Fisher’s exact test)
Surgical diagnosis, n (%)
Nodular goiter 31 (62%) 31 (62%)
Toxic goiter 0 (0%) 1 (2%) 0.493 (likelihood ratio)
Differentiated carcinoma 19 (38%) 18 (36%)
Difficult airway and intubation with bronchoscopy, n (%) 0 (0%) 2 (4%) 0.495 (Fisher’s exact test)
Legend: SD, standard deviation; BMI, body mass index.
3
CLINICS 2019;74:e605 Superficial cervical plexus blockade
Goulart TF et al.
of G2 patients (p=0.006; Fisher’s exact test). After 60 minutes,
there was no significant difference.
In the PACU at 45 and 60 minutes, 16% of the patients in
G1 had nausea and vomiting (PONV 3 or 4) compared to 0%
of G2 patients (p=0.006 for both analyses; Fisher’s exact test).
In G1, there was 1 case of cervical hematoma in the first
60 minutes (2%). No cases of hematoma were observed in
G2. However, this was not a significant difference. The single
case was not treated surgically because it was a small, stable
subcutaneous hematoma. In the PACU, there were no cases
of dyspnea in either group.
The complete analyses of both groups in the PACU are
described in Table 3.
Data from the IU
There were no significant differences between the main
NIABP, HR, or temperature between the G1 and G2 patients
in the IU.
At 4 hours after arrival, 20% of G1 patients reported pain
(VAS43), and an additional opioid dose was necessary. In
G2, only 6% of patients reported pain (p=0.037; Fisher’s exact
test). At the other time points (after 4 hours), there was no
significant difference.
Opioid consumption between the groups had the same
behavior as the pain scores. In G1, 4 hours after arrival, 20%
of patients requested nalbuphine, while only 6% of patients
in G2 requested nalbuphine (p=0.037; Fisher’s exact test).
After 8 and 12 hours, there were no differences in opioid
consumption between the groups.
G1 patients had significantly more nausea and vomiting
(PONV 3 or 4) than G2 patients during the postoperative
period. In G1, 18% and 14% of patients reported PONV at
4 and 8 hours, respectively, compared to 0% of patients in
G2 (p=0.003 and p=0.012, respectively; Fisher’s exact test).
There was no significant difference in the incidence of
hematoma in the IU. Upon arrival, only 1 case of hematoma
had occurred, corresponding to the same case in the PACU
(2%). After 4 hours, another case of hematoma occurred in
G1. After 12 hours, the incidence of hematoma was 4% in G1
and 0% in G2. Neither case required surgical re-exploration
because both were small subcutaneous hematomas. There
were no cases of dyspnea or shivering in either group.
The complete analysis of the IU period is shown in Table 4.
’ DISCUSSION
Recent studies have correlated pain, thyroidectomy, and
BSCPB (5-10), but the efficacy of BSCPB for the postoperative
period remains controversial. The present study demon-
strated that patients undergoing BSCPB in combination with
general anesthesia had increased pain control, reduced opioid
consumption, and a reduced incidence of nausea and vomiting.
First, it is important to note that this study was a
prospective study and that the period of observation was
during the hospital stay, and data acquisition was performed
by a single team. Moreover, there were no dropout or
missing patients in the study, and only patients with ASA I
(healthy) or ASA II (systemic disease compensated) were
included. Patients with rheumatic or neurological diseases
(central or peripheral) and patients being treated for chronic
pain or other conditions were excluded.
Upon PACU arrival, almost no patients reported pain
in either group, possibly due to the residual effects of the
anesthesia administered in the OR. However, the VAS scores
and opioid consumption (nalbuphine) were significantly
lower for PACU and IU patients than for BSCPB patients.
Gürkan et al. (9) first demonstrated an association between
BSCPB and a reduction in opioid consumption. Opioid
consumption was related to pain scores reported by patients
in the present study. If the VAS score was43, one dose was
administered after each evaluation. It is also possible to
correlate the lower pain scores reported by G2 patients with
the hemodynamic parameters in the PACU. The NIABP
and HR of the patients who received the blockade were
12% lower than those of the patients who received general
anesthesia, and opioid consumption reduction was 70%,
probably because the adrenergic response caused by post-
operative stress (pain) was less intense.
Sardar et al. (11) demonstrated no differences between
groups under general anesthesia and groups under general
anesthesia combined with BSCPB. However, the authors
used just 15 ml 0.25% bupivacaine, and the anesthesia
gradually becomes less potent with the gradual reduction in
local anesthetic concentration; this method does not reflect
effective pain control at the PACU and IU. Based on that,
the difference in pain control found in the present study
in patients treated with BSCPB could be justified because we
used ropivacaine at a concentration of 0.75%, which leads to
a longer lasting anesthetic effect.
Mukhopadhyay et al. (12) demonstrated no advantage of
BSCPB for thyroid surgeries. In that study, patients under-
went blockade with 0.5% ropivacaine. However, the techni-
que applied included two punctures with a total volume of
6 ml on each side. In a blockade, it is important that the
anesthetic is spread to as many fibers as possible. The spread
of anesthetic is proportional to its volume. In the present
Table 2 - Noninvasive arterial blood pressure (NIABP), heart rate (HR), and temperature in the operating room (OR).
Variable Group 1 Group 2 p-value (test)
NIABP, mean ± SD, mmHg
M1 82.9±10.8 85.1±10.1
M2 65.2±12.5 68.8±12.6 0.562 (rm-ANOVA)
M3 83.6±11.6 86.2±12.5
HR, mean ± SD, bpm
M1 63.6±9.9 66.4±8.1
M2 62.9±9.9 65.2±11.1 0.756 (rm-ANOVA)
M3 71.8±9.8 74.3±10.3
Temperature, mean ± SD, oC
M1 36.2±0.2 36.3±0.2
M2 36.2±0.2 36.2±0.3 0.083 (rm-ANOVA)
M3 36.2±0.2 36.0±0.3
Legend: SD, standard deviation; rm-ANOVA, repeated measures ANOVA.
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study, 10 ml of ropivacaine was administered on each side.
Nevertheless, Mukhopadhyay et al. (12) compared the blo-
ckade, the sole anesthetic technique, with general anesthesia.
In our study, all patients received general anesthesia. The
blockade was added to compare the postoperative condi-
tions and patient outcomes. Moreover, no blockade compli-
cations were observed.
The volume and concentration of the anesthetic are
important for local anesthetic efficacy (13). Herbland et al.
(14) demonstrated no efficacy of the blockade with 0.75%
ropivacaine in relieving postoperative pain for 36 hours
after the operation. The present study evaluated only the first
12 postoperative hours.
Cai et al. (7) demonstrated an association between BSCPB
and a reduction in PONV, and this association corroborates
the findings of the present study. Nausea and vomiting
appeared late in the PACU and was more frequent in those
patients not submitted to BSCPB. G2 patients reported lower
pain scores (VASo3) over time, consumed fewer opioids,
and presented with fewer side effects, such as nausea
and vomiting, than G1 patients. This observation may occur
because PONV is likely a side effect of opioid administration;
furthermore, these attributes are cumulative and time- and
dose-dependent.
More recent studies have demonstrated the efficacy of
the blockade for thyroidectomies. Kannan et al. (15) demon-
strated a reduced use of sevoflurane during surgery, and
Awekes et al. (16) demonstrated a reduced use of periopera-
tive opioids, namely, during the surgery and the postopera-
tive period.
However, a relevant aspect of the present study must be
considered. The anesthetic technique used during the pro-
cedure in both groups was TIVA. With this technique, anes-
thesia is induced with a single dose of fentanyl (2 mcg/kg)
and maintained with a continuous infusion of propofol
and remifentanil. As a result, there is no residual effect of
analgesia in the recovery room. All the previously mentioned
studies used sevoflurane (balanced anesthesia technique) or
repeated fentanyl doses for the maintenance of anesthesia
during the surgery. Sevoflurane maintenance and addi-
tional doses of fentanyl provide residual analgesic effects in
the postoperative period, mainly in the recovery room. It is
Table 3 - Noninvasive arterial blood pressure (NIABP), heart rate (HR), temperature, pain scores (VAS43), opioid (nalbuphine)
consumption, postoperative nausea and vomiting (PONV), and cervical hematoma in the postanesthesia care unit (PACU).
Variable Group 1 Group 2 p-value (test)
NIABP, mean ± SD, mmHg o0.001 (rm-ANOVA)
Arrival 88.7±13.0 88.1±13.7 0.856 (Bonferroni)
15 minutes 100.7±14.6 90.2±10.8 o0.001 (Bonferroni)
30 minutes 103.8±11.3 92.2±10.7 o0.001 (Bonferroni)
45 minutes 101.1±10.5 91.6±11.9 o0.001 (Bonferroni)
60 minutes 101.0±11.1 92.3±10.4 o0.001 (Bonferroni)
HR, mean ± SD, bpm o0.001 (rm-ANOVA)
Arrival 87.4±9.2 74.2±6.0 o0.001 (Bonferroni)
15 minutes 87.8±8.9 75.3±6.1 o0.001 (Bonferroni)
30 minutes 88.4±8.4 77.2±7.1 o0.001 (Bonferroni)
45 minutes 87.9±9.3 77.5±7.4 o0.001 (Bonferroni)
60 minutes 87.9±8.9 78.0±6.8 o0.001 (Bonferroni)
Temperature, mean ± SD, oC 0.314 (rm-ANOVA)
Arrival 36.0±0.3 35.9±0.4 -
15 minutes 36.0±0.3 35.9±0.3 -
30 minutes 36.1±0.2 36.0±0.3 -
45 minutes 36.2±0.2 36.1±0.2 -
60 minutes 36.3±0.2 36.1±0.2 -
Pain scores (VAS43), n (%)
Arrival 10 (20%) 4 (8%) 0.084 (Fisher’s exact test)
15 minutes 28 (56%) 3 (6%) o0.001 (Fisher’s exact test)
30 minutes 17 (34%) 1 (2%) o0.001 (Fisher’s exact test)
45 minutes 8 (16%) 0 0.006 (Fisher’s exact test)
60 minutes 4 (8%) 0 0.117 (Fisher’s exact test)
Opioid (nalbuphine) consumption, n (%)
Arrival 10 (20%) 4 (8%) 0.084 (Fisher’s exact test)
15 minutes 28 (56%) 3 (6%) o0.001 (Fisher’s exact test)
30 minutes 17 (34%) 1 (2%) o0.001 (Fisher’s exact test)
45 minutes 8 (16%) 0 0.006 (Fisher’s exact test)
60 minutes 4 (8%) 0 0.117 (Fisher’s exact test)
PONV, n (%)
Arrival 0 2 (4%) 0.495 (Fisher’s exact test)
15 minutes 1 (2%) 1 (2%) 1.000 (Fisher’s exact test)
30 minutes 5 (10%) 2 (4%) 0.436 (Fisher’s exact test)
45 minutes 8 (16%) 0 0.006 (Fisher’s exact test)
60 minutes 8 (16%) 0 0.006 (Fisher’s exact test)
Cervical hematoma, n (%)
Arrival 0 0 -
15 minutes 0 0 -
30 minutes 0 0 -
45 minutes 1 (2%) 0 1.000 (Fisher’s exact test)
60 minutes 1 (2%) 0 1.000 (Fisher’s exact test)
Legend: SD, standard deviation; rm-ANOVA, repeated measures ANOVA; Bonferroni, Bonferroni’s post hoc test.
5
CLINICS 2019;74:e605 Superficial cervical plexus blockade
Goulart TF et al.
possible that the analgesic effects demonstrated by previous
studies were not the unique effect of the cervical plexus
blockade but were the additional residual effects of the
opioids and inhaled drugs from the anesthetic technique
applied in the OR.
Mayhew et al. (17) demonstrated the analgesic efficacy
of the blockade in a meta-analysis. However, the general
anesthesia technique used was not mentioned or compared.
This important aspect may influence analgesia during the
earlier postoperative period. The meta-analysis did not find
a reduction in PONV, contrary to the results of the present
study. PONV is related to the amount of opioids used (side
effects) and to the anesthesia technique used (18).
Senapathi et al. (19) and Gürkan et al. (9) compared the
efficacy of the blockade between the standard and the
ultrasound-guided technique. In fact, the ultrasound-guided
technique is an additional step that will be tested after the
conclusion of this study.
The present study has some important limitations. Nota-
bly, no sample size estimation was performed a priori. In
fact, authors designed the study to be one of the largest in
this specific literature category. Additionally, other limita-
tions may include problems with concealment and blinding
procedures, the absence of a placebo control group, the
simple randomization method and the risk of imbalance
between groups.
In conclusion, the present study demonstrated that BSCPB
using the landmark technique associated with TIVA for
thyroidectomy is feasible, safe, and effective for improving
patient outcomes based on pain control, reduced opioid con-
sumption during the first 4 postoperative hours, and reduced
nausea and vomiting during the first 8 hours of the post-
operative period.
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